Tenaya Therapeutics Stock News

Tenaya Therapeutics (TNYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Tenaya Therapeutics Inc (TNYA) shares closed this week 20.8% lower than it did at the end of last week. The stock is currently down 47.2% year-to-date, down 34.9% over the past 12 months, and down 34.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.2%. Trading Activity Shares traded as high as $13.76 and as low as $9.25 this week.Trading volume this week was 13.2% lower than the 10-day average and 20.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7759.0% The company's stock price performance over the past 12 months lags the peer average by 128.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Tenaya Therapeutics Inc (NASDAQ:TNYA)s stock price traded up 7.7% during mid-day trading on Wednesday . The company traded as high as $20.74 and last traded at $20.74. 702 shares changed hands during trading, a decline of 100% from the average session volume of 171,013 shares. The stock had previously closed at $19.26. Separately, Zacks Investment []

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , PTGX , MDXG , CSTL , AGEN , ABUS , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. announces the appointments of Karah Parschauer to its Board of Directors and of Joanna Auch as SVP of People and Culture.

Tenaya Therapeutics (NASDAQ:TNYA) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Insider and Institutional Ownership 34.7% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 95.3% []

Tenaya Therapeutics Inc (NASDAQ:TNYA)s share price gapped up prior to trading on Tuesday . The stock had previously closed at $18.69, but opened at $19.49. Tenaya Therapeutics shares last traded at $19.61, with a volume of 79 shares changing hands. Several analysts have recently weighed in on the company. Chardan Capital assumed coverage on Tenaya []

Tenaya Therapeutics (NASDAQ:TNYA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Analyst Ratings This is a breakdown of recent ratings and price targets for Tenaya Therapeutics []

Zacks Investment Research upgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in the 33rd Annual Piper Sandler Healthcare Conference.

Adverum Biotechnologies (NASDAQ:ADVM) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Earnings & Valuation This table compares Adverum Biotechnologies and Tenaya Therapeutics top-line revenue, earnings per []

Zacks Investment Research upgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) from a sell rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The companys []

Tenaya Therapeutics Inc (NASDAQ:TNYA) Investment analysts at Piper Sandler decreased their FY2021 earnings per share estimates for Tenaya Therapeutics in a report issued on Wednesday, November 10th. Piper Sandler analyst Y. Rahimi now forecasts that the company will earn ($14.99) per share for the year, down from their previous estimate of ($14.42). Piper Sandler []

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,

Related Stocks: PDD , TNYA , SRZN , DNLI , CNST , SNOW , NRIX , BEAM , VIR ,